CureVac N.V.

CureVac N.V. (CVAC) priced its initial public offering on Aug 14, 2020 at $16.00 per share, within its $14.00–$16.00 range, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $2.82B. BofA Securities was lead-left underwriter, joined by Jefferies and Credit Suisse. Davis Polk advised the company and Latham & Watkins advised the underwriters.

CureVac N.V. is a clinical-stage biopharmaceutical company developing medicines based on messenger RNA (mRNA), designed to prevent infections and treat diseases by having the body make the proteins it needs. Its portfolio includes clinical and preclinical candidates across multiple disease indications.

Status

IPO

Ticker

CVAC

Exchange

Nasdaq Global Market

Priced

Aug 14, 2020

IPO price

$16.00

Price range

$14.00–$16.00

Market cap at IPO price

$2.82B

First filed

Jul 24, 2020

Underwriters

BofA Securities, Jefferies and Credit Suisse

Company counsel

Davis Polk

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.